Divergent label-free cell phenotypic pharmacology of ligands at the overexpressed β 2 -adrenergic receptors

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Ferrie, Ann M ^a   Sun, Haiyan ^a   Zaytseva, Natalya ^a   Fang, Ye ^a  

^a Corning Incorporated ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CYCLIC AMP; ENHANCED GREEN FLUORESCENT PROTEIN; EPINEPHRINE; G PROTEIN COUPLED RECEPTOR; GREEN FLUORESCENT PROTEIN; GUANINE NUCLEOTIDE EXCHANGE FACTOR; LIGAND; RAPGEF3 PROTEIN, HUMAN;

ACTIN FILAMENT; CHEMISTRY; DRUG EFFECTS; FLOW CYTOMETRY; HEK293 CELL LINE; HUMAN; METABOLISM; MICROTUBULE; PHENOTYPE; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ACTIN CYTOSKELETON; ADRENERGIC BETA-AGONISTS; BLOTTING, WESTERN; CYCLIC AMP; EPINEPHRINE; FLOW CYTOMETRY; GREEN FLUORESCENT PROTEINS; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HEK293 CELLS; HUMANS; LIGANDS; MICROTUBULES; PHENOTYPE; PROTEIN TRANSPORT; RECEPTORS, ADRENERGIC, BETA-2; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 84893117844     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep03828     Document Type: Article

References (68)

1. Drewsm, J. Drug discovery: a historical perspective. Science 287, 1960-1964 (2000)
2. Overington, J. P., Al-Lazikani, B. & Hopkins, A. L. How many drug targets are there? Nat. Rev. Drug Discov. 5, 993-996 (2006) (Pubitemid 44835126)
3. Rajagopal, S., Rajagopal, K. & Lefkowitz, R. J. Teaching old receptors new tricks: biasing seven-transmembrane receptors. Nat. Rev. Drug Discov. 9, 373-386 (2010)
4. Kenakin, T. & Miller, L. J. Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol. Rev. 62, 265-304 (2010)
5. Urban, J. D. et al. Functional selectivity and classical concepts of quantitative pharmacology. J. Pharmacol. Exp. Ther. 320, 1-13 (2007) (Pubitemid 46025713)
6. Kenakin, T. P. Biased signalling and allosteric machines: new vistas and challenges for drug discovery. Br. J. Pharmacol. 165, 1659-1669 (2012)
7. Kelly, E. Efficacy and ligand bias at the m-opioid receptor. Br. J. Pharmacol. 169, 1430-1446 (2013)
8. Seifert, R., Gether, U., Wenzel-Seifert, K. & Kobilka, B. K. Effects of guanine, inosine, and xanthine nucleotides on b2-adrenergic receptor/Gs interactions: evidence for multiple receptor conformations. Mol. Pharmacol. 56, 348-358 (1999) (Pubitemid 29347611)
9. Azzi, M. et al. b-Arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein coupled receptors. Proc. Natl. Acad. Sci. USA 100, 11406-11411 (2003) (Pubitemid 37205948)
10. Baker, J. G.,Hall, I. P. & Hill, S. J. Agonist and inverse agonist actions of b-blockers at the human b2-adrenoceptor provide evidence for agonist-directed signaling. Mol. Pharmacol. 64, 1357-1369 (2003) (Pubitemid 37532226)
11. Galandrin, S. & Bouvier, M. Distinct signaling profiles of b1 and b2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy. Mol. Pharmacol. 70, 1575-1584 (2006)
12. Wisler, J. W. et al. A unique mechanism of beta-blocker action: carvedilol stimulates b-arrestin signaling. Proc. Natl. Acad. Sci. USA 104, 16657-16662 (2007)
13. Kim, I. M. et al. b-blockers alprenolol and carvedilol stimulate b-arrestinmediated EGFR transactivation. Proc. Natl. Acad. Sci. USA 105, 14555-14560 (2008)
14. Drake, M. T. et al. b-Arrestin-biased agonism at the b2-adrenergic receptor. J. Biol. Chem. 283, 5669-5676 (2008)
15. Evans, B. A., Sato, M., Sarwar, M., Hutchinson, D. S. & Summers, R. J. Liganddirected signalling at b2-adrenoceptors. Br. J. Pharmacol. 159, 1022-1038 (2010)
16. Reiner, S., Ambrosio, M.,Hoffmann, C. & Lohse, M. J. Differential signaling of the endogenous agonists at the b2-adrenergic receptor. J. Biol. Chem. 285, 36188-36198 (2010)
17. Patel, C. B., Noor, N. & Rockman, H. A. Functional selectivity in adrenergic and angiotensin signaling systems. Mol. Pharmacol. 78, 983-992 (2010)
18. Reiter, E., Ahn, S., Shukla, A. K. & Lefkowitz, R. J. Molecular mechanism of barrestin- biased agonism at seven-transmembrane receptors. Ann. Rev. Pharmacol. Tox. 52, 179-197 (2012)
19. Brunskole, H. I. et al. Dissociations in the effects of b2-adrenergic receptor agonists on cAMP formation and superoxide formation in human neutrophils: Support for the concept of functional selectivity. PLoS One 8, e64556 (2013)
20. Fang, Y.& Ferrie, A. M. Label-free optical biosensor for ligand-directed functional selectivity acting on b2 adrenoceptor in living cells. FEBS Lett. 582, 558-564 (2008)
21. Goral, V. et al. Agonist-directed desensitization of the b2-adrenergic receptor. PLoS One 6, e19282 (2011)
22. Stallaert, W., Dorn, J. F., van Westhuizen, E., Audet, M. & Bouvier, M. Impedance responses reveal b2-adrenergic receptor signalling pluridimensionality and allow classification of ligands with distinct signalling profiles. PLoS One 7, e29420 (2012)
23. Ferrie, A. M., Wang, C., Deng, H. & Fang, Y. Label-free optical biosensor with microfluidics identifies an intracellular signalling wave mediated through the b2- adrerengic receptor. Integr. Biol. 5, 1253-1261 (2013)
24. Kahsai, A. et al. Multiple ligand-specific conformations of the b2-adrenergic receptor. Nature Chem. Biol. 7, 692-700 (2011)
25. West, G. M. et al. Ligand-dependent perturbation of the conformational ensemble for the GPCR b2-adrenergic receptor revealed by HDX. Structure 19, 1424-1432 (2011)
26. Rasmussen, S. G. et al. Crystal structure of the b2 adrenergic receptor-Gs protein complex. Nature 477, 549-555 (2011)
27. Zocher, M., Fung, J. J., Kobilka, B. K. & Muller, D. J. Ligand-specific interactions modulate kinetic, energetic, and mechanical properties of the human b2 adrenergic receptor. Structure 20, 1391-1402 (2012)
28. Liu, J. J., Horst, R., Katritch, V., Stevens, R. C. & Wuthrich, K. Biased signalling pathways in b2-adrenergic receptor characterized by 19F-NMR. Science 335, 1106-1110 (2012)
29. Kolinski, M., Plazinska, A. & Jozwiak, K. Recent progress in understanding of structure, ligand interactions and the mechanism of activation of the b2- adrenergic receptor. Curr. Med. Chem. 19, 1155-1163 (2012)
30. Kofuku, Y. et al. Efficacy of the b2-adrenergic receptor is determined by conformational equilibrium in the transmembrane region. Nature Comm. 3, e1045 (2012)
31. Nygaard, R. et al. The dynamic process of b2-adrenergic receptor activation. Cell 152, 532-542 (2013)
32. Venkatakrishnan, A. J. et al.Molecular signatures of G-protein-coupled receptors. Nature 494, 185-194 (2013)
33. Deupi, X. & Kobilka, B. K. Energy landscape as a tool to integrate GPCR structure, dynamics and function. Physiology 25, 293-303 (2010)
34. Kenakin, T. The potential for selective pharmacological therapies through biased receptor signaling. BMC Pharmacol. Tox. 13, 3 (2012)
35. Kenakin, T. & Christopoulos, A. Signalling bias in new drug discovery: detection, quantification and therapeutic impact. Nat. Rev. Drug Discov. 12, 205-216 (2013)
36. Fang, Y., Ferrie, A. M., Fontaine, N. H., Mauro, J. & Balakrishnan, J. Resonant waveguide grating biosensor for living cell sensing. Biophys. J. 91, 1925-1940 (2006) (Pubitemid 44352454)
37. Fang, Y. The development of label-free cellular assays for drug discovery. Expert Opin. Drug Discov. 6, 1285-1298 (2011)
38. Fang, Y., Ferrie, A. M., Fontaine, N. H. & Yuen, P. K. Characteristics of dynamic mass redistribution of epidermal growth factor receptor signaling in living cells measured with label-free optical biosensors. Anal. Chem. 77, 5720-5725 (2005) (Pubitemid 41266070)
39. Schroder, R. et al. Deconvolution of complex G protein-coupled receptor signaling in live cells using dynamic mass redistribution measurements. Nat. Biotechnol. 28, 943-949 (2010)
40. Verrier, F. et al. G protein-coupled receptor signaling regulates the dynamics of a metabolic multienzyme complex. Nature Chem. Biol. 7, 909-915 (2011)
41. Kenakin, T. Cellular assays as portals to seven-transmembrane receptor-based drug discovery. Nat. Rev. Drug Discov. 8, 617-626 (2009)
42. Ferrie, A. M., Sun, H. & Fang, Y. Label-free integrative pharmacology on-target of drugs at the b2-adrenergic receptor. Sci. Rep. 1, 33 (2011)
43. Morse, M., Tran, E., Levension, R. L. & Fang, Y. Ligand-directed functional selectivity at the mu opioid receptor revealed by label-free on-target pharmacology. PLoS One 6, e25643 (2011)
44. Morse, M., Sun, H., Tran, E., Levenson, R. & Fang, Y. Label-free integrative pharmacology ontarget of opioid ligands at the opioid receptor family. BMC Pharmacol. Tox. 14, 17 (2013)
45. von Zastrow, M. & Kobilka, B. K. Ligand-regulated internalization and recycling of human b2-adrenergic receptors between the plasmamembrane and endosomes containing transferrin receptors. J. Biol. Chem. 267, 3530-3538 (1992)
46. Eisen, M. B., Spellman, P. T., Brown, P. O. & Botstein, D. Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. USA 95, 14863-14868 (1998) (Pubitemid 29003722)
47. PDSP Ki database. . http://pdsp.med.unc.edu/pdsp.php
48. Cecchetti, V., Schiaffella, F., Tabarrini, O. & Fravolini, A. (1,4-Benzothiazinyloxy) alkylpiperazine derivatives as potential antihypertensive agents. Bioorg. Med. Chem. Lett. 10, 465-468 (2000) (Pubitemid 30153614)
49. Ruffolo, R. R. Jr. & Waddell, J. E. Receptor interactions of imidazolines. IX. Cirazoline is an a1 adrenergic agonist and an a2 adrenergic antagonist. J. Pharmacol. Exp. Ther. 222, 29-36 (1982) (Pubitemid 12096994)
50. Zaytseva, Z. et al. Resonant waveguide grating biosensor-enabled label-free and fluorescence detection of cell adhesion. Sens. Actuators B: Chem. 188, 1064-1072 (2013)
51. Fang, Y. Label-free receptor assays. Drug Discov. Today Technol. 7, e5-e11 (2010)
52. Chen, M. et al. Microplate-compatible total internal reflection fluorescence microscopy for receptor pharmacology. Appl. Phys. Lett. 102, 193702 (2013)
53. Bos, J. L. Epac proteins: multi-purpose cAMP targets. Trends Biochem. Sci. 31, 680-686 (2006) (Pubitemid 44791945)
54. Ponsioen, B., Gloerich, M., Ritsma, L. & Rehmann, H. Direct spatial control of Epac1 by cyclic AMP. Mol. Cell. Biol. 29, 2521-2531 (2009)
55. Zhong, N. & Zucker, R. S. cAMP acts on exchange protein activated by cAMP/ cAMP-regulated guanine nucleotide exchange protein to regulate transmitter release at the crayfish neuromuscular junction. J. Neurosci. 25, 208-214 (2005) (Pubitemid 40110782)
56. Ster, J. et al. Epac mediates PACAP-dependent long-term depression in the hippocampus. J. Physiol. 587, 101-113 (2009)
57. Kinzer-Ursem, T. L. & Linderman, J. J. Both ligand- and cell-specific parameters control ligand agonism in a kinetic model of G protein-coupled receptor signaling. PLoS Comput. Biol. 3, e6 (2007)
58. Daaka, Y., Luttrell, L. M. & Lefkowitz, R. J. Switching of the coupling of the b2- adrenergic receptor to differentGproteins by protein kinase A. Nature 390, 88-91 (1997) (Pubitemid 27494762)
59. Friedman, J., Babu, B. & Clark, R. B. b2-Adrenergic receptor lacking the cyclic AMP-dependent protein kinase consensus sites fully activates extracellular signalregulated kinase 1/2 in human embryonic kidney 293 cells: Lack of evidence for Gs/Gi switching. Mol. Pharmacol. 62, 1094-1102 (2002) (Pubitemid 35222500)
60. Tran, E. & Fang, Y. Duplexed label-freeGprotein-coupled receptor assays for high throughput screening. J. Biomol. Screen. 13, 975-985 (2008)
61. Kholodenko, B. N., Hancock, J. F. & Kolch, W. Signalling ballet in space and time. Nat. Rev. Mol. Cell Biol. 11, 414-426 (2010)
62. Giraldo, J. On the fitting of binding data when receptor dimerization is suspected. Br. J. Pharmacol. 155, 17-23 (2008)
63. Nishino, Y. et al. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study. BJU Int. 97, 747-751 (2006) (Pubitemid 43383507)
64. Keiper, M. et al. Epac- and Ca21-controlled activation of Ras and extracellular signal-regulated kinases by Gs-coupled receptors. J. Biol. Chem. 279, 46497-46508 (2004) (Pubitemid 39518293)
65. Grandoch, M., Roscioni, S. S. & Schmidt, M. The role of Epac proteins, novel cAMP mediators, in the regulation of immune, lung and neuronal function. Br. J. Pharmacol. 159, 265-284 (2010)
66. Rangarajan, S. et al. Cyclic AMP induces integrin-mediated cell adhesion through Epac and Rap1 upon stimulation of the b2-adrenergic receptor. J. Cell Biol. 160, 487-493 (2003) (Pubitemid 36254387)
67. Fang, Y. Troubleshooting and deconvoluting label-free cell phenotypic assays in drug discovery. J. Pharmacol. Tox. Methods 67, 69-81 (2013)
68. Li, G., Ferrie, A. M. & Fang, Y. Label-free profiling of endogenous G proteincoupled receptors using a cell-based high throughput screening technology. J. Assoc. Lab. Autom. 11, 181-187 (2006) (Pubitemid 44184986)